Biotest AG

Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest’s plasma center in Darmstadt and call for plasma donations

Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million

Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged

Biotest and SteinCares partner to improve access to plasma-derived products in Latin America

Strategic agreement signed for distribution of Yimmugo® in the United States based on the framework established in July

Change in the Chief Financial Officer at Biotest AG

Biotest AG opens 13th plasma collection center in Germany

Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG

Biotest increases sales in the first half of 2024 by 35% to Euro 372 million

Biotest increases sales in the first half of 2024 by 35% to Euro 372 million

Biotest prepares launch of its immunoglobulin Yimmugo in the USA, establishing a framework for a strategic billion-dollar distribution agreement with Kedrion

Biotest’s sustainability campaign GoFuture part of the new documentary ‘Future Seeds’

Milestone for Biotest: US approval for innovative immunoglobulin Yimmugo

Biotest AG: Annual General Meeting approves dividend distribution

Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024

Biotest AG opens 12th plasma collection centre in Germany

Biotest Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 07.05.2024 in Frankfurt am Main mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Biotest AG increased sales by 32% in the financial year 2023

Biotest achieves EBIT forecast for 2023

Karl Lauterbach visits Biotest AG’s plasma donation centre in Cologne and emphasises important contribution to patient care

Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate

Biotest AG opens 11th plasma collection centre in Germany

Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)

Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation

Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023

Biotest AG: Increase of the EBIT guidance